Gapping up
In reaction to earnings/guidance:
- UPST +37.4%, LZ +13.8%, CARG +11.2%, CELH +10.6%, FLYW +10%, TBLA +8.8%, SYNH +8.8%, MNKD +8.2%, IAC +8.1%, EXAS +8%, RIVN +7.7% (also files mixed shelf securities offering), EVRI +7.7%, WWW +7%, NABL +7%, KIND +6.8%, RNG +6.6%, LPSN +6.4%, GH +6.3%, LI +6.3%, GO +6.1%, COMP +6.1%, ALC +5.6%, PUBM +5.6%, LNW +5.3%, AKAM +5.2% (also announces 3% workforce reduction), TOST +5.1%, VVV +5%, SUPN +4.8%, PRIM +4.5%, XMTR +4.4%, ZD +3.9%, NTRA +3.7%, DUOL +3.5%, BAM +3.5%, EA +3.3%, MODN +3.3%, SHCR +3.3%, HALO +3.2%, OSCR +3.1%, VVX +3.1%, VTLE +2.9%, DAR +2.9%, QTWO +2.7%, NHI +2.6%, MIDD +2.6%, OLO +2.5%, CLBT +2.2%, CTOS +2.1%, PETQ +2%, AGTI +2%, DIOD +2%, LPRO +2%, KGC +1.9%, CE +1.8%, CDRE +1.8%, TM +1.7%, IOVA +1.6%, ONL +1.6%, DIBS +1.4%, BCO +1.4%, APPN +1.1%, TWNK +1.1% (also authorizes new $150 mln share repurchase program), XENE +1.1%, LFST +1.1%, VZIO +1%
Other news:
- CTIC +84% (to be acquired by Sobi for $9.10 per share)
- SYNH +8.8% (confirms acquisition by consortium including Elliott Investment Management for $43/share)
- PLX +7.9% (Chiesi Global Rare Diseases and PLX announce the FDA has approved ELFABRIO (pegunigalsidase alfa-iwxj) for the treatment of adult patients with Fabry disease)
- BEN +4% (reports April AUM)
- TBPH +2.8% (FDA grants orphan drug designation for Ampreloxetine)
- BWEN +1.3% (Sends Letter to Shareholders Clarifying Attempts by WM Argyle to Mislead Shareholders)
- W +1.2% (announces the pricing of $600 mln aggregate principal amount of 3.50% convertible senior notes due 2028 in a private offering)
- ALVO +1% (enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea)
Analyst comments:
- IDCC +3.1% (upgraded to Buy from Neutral at BofA Securities)